Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TXNRD1 | Q16881 | 6/20 | 0.43 |
| ▸ | TXNRD3 | Q86VQ6 | 6/20 | 0.43 |
| ▸ | TXNRD2 | Q9NNW7 | 6/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | FGF1 | P05230 | 3/20 | 0.35 |
| ▸ | FGF2 | P09038 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9099489 | 0.98 | ALDH1A1 (0.48) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL7625544 | 0.95 | FYN (0.40) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL7628032 | 0.95 | FYN (0.40) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL29350097 | 0.94 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL432885 | 0.89 | ALDH1A1 (0.62) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL1056613 | 0.89 | ALDH1A1 (0.62) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL398655 | 0.89 | ALDH1A1 (0.62) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL2305805 | 0.89 | ALDH1A1 (0.62) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Ammonia Solution, Strong SCHEMBL19100890 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Ammonia Solution, Strong SCHEMBL19100618 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRLMNATDP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 642 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150132797-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | LIFE TECHNOLOGIES CORP (US) | 2015-05-14 | — | — | US | claimed |
| US-20080038773-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | INVITROGEN CORPORATION (US) | 2008-02-14 | — | — | US | claimed |
| US-20080038772-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | INVITROGEN CORPORATION (US) | 2008-02-14 | — | — | US | claimed |
| US-5874419-A | ADMINISTERING LOCALLY TO THE TISSUE A POLYANIONIC CYCLODEXTRIN DERIVATIVE IN A PHYSIOLOGICALLY ACCEPTABLE CARRIER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1999-02-23 | — | — | US | claimed |
| EP-0423240-B1 | MODULATION OF VIRUS-HOST CELL INTERACTIONS USING CYCLIC OLIGOSACCHARIDES | UNIV PENNSYLVANIA (US) | 1995-11-08 | — | — | EP | claimed |
| US-5183809-A | Polyionic sulfated derivatives of cyclodextrin; affinity chromatography for separation of proteins, e.g. growth factors; protein storage; drug delivery | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA/CHILDRENS HOSPITAL CORPORATION (US) | 1993-02-02 | — | — | US | claimed |
| EP-0423240-A4 | METHOD OF MODULATING VIRUS-HOST CELL INTERACTIONS USING CARBOHYDRATES AND CARBOHYDRATE DERIVATIVES | — | 1992-07-22 | — | — | EP | claimed |
| EP-0423240-A1 | MODULATION OF VIRUS-HOST CELL INTERACTIONS USING CYCLIC OLIGOSACCHARIDES. | UNIV PENNSYLVANIA (US) | 1991-04-24 | — | — | EP | claimed |
| WO-1990000596-A1 | METHOD OF MODULATING VIRUS-HOST CELL INTERACTIONS USING CARBOHYDRATES AND CARBOHYDRATE DERIVATIVES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1990-01-25 | — | — | WO | claimed |
| EP-3325513-B1 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF | I MAB BIOPHARMA CO LTD (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116987-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-0423240-A1 | MODULATION OF VIRUS-HOST CELL INTERACTIONS USING CYCLIC OLIGOSACCHARIDES. | UNIV PENNSYLVANIA (US) | 1991-04-24 | — | — | EP | disclosed |
| EP-0360006-A2 | Acid-resistant fibroblast growth factor composition for treating ulcerating diseases of the gastrointestinal tract | Takeda Chemical Industries, Ltd. (JP) | 1990-03-28 | — | — | EP | disclosed |
| WO-1990001941-A1 | ACID-RESISTANT FGF COMPOSITION AND METHOD OF TREATING ULCERATING DISEASES OF THE GASTROINTESTINAL TRACT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1990-03-08 | — | — | WO | disclosed |
| WO-1990000596-A1 | METHOD OF MODULATING VIRUS-HOST CELL INTERACTIONS USING CARBOHYDRATES AND CARBOHYDRATE DERIVATIVES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1990-01-25 | — | — | WO | disclosed |
| EP-0325199-A2 | Fumagillin as angiostatic agent | Takeda Chemical Industries, Ltd. (JP) | 1989-07-26 | — | — | EP | disclosed |
| EP-0325199-A2 | Fumagillin as angiostatic agent | Takeda Chemical Industries, Ltd. (JP) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116987-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | CCR8, VSIG8, CCR3 | ALDH1A1 3700/4885TSHR 501/4885LMNA 3007/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | ALDH1A1 3668/4885TSHR 1424/4885LMNA 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.